QIAGEN N.V.
QGENNYSETrading Snapshot
- Day Range
- $44.20 β $44.79
- 52-Week Range
- $32.53 β $57.82
- Volume
- $3.28B
- Avg Volume
- $3.09B
- Shares Outstanding
- 206.3M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.09B
- Last Q Revenue
- $535M
- P/E Ratio
- 23.1
- P/S Ratio
- 4.4x
- EPS (TTM)
- $1.98
- Dividend Yield
- 5.87%
- Dilution (1yr)
- β4.7%
Why Investors Own QGEN
- βHigh-growth profile β revenue up +22.1% YoY with expanding US Equity exposure.
- βHealthy economics β 30% gross margin and 8% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
QIAGEN N.V.
QGENAbout QIAGEN N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstre

Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51
Qiagen N.V. (NYSE: QGEN - Get Free Report) has been given an average rating of "Hold" by the fourteen brokerages that are covering the company, Marketbeat reports. Nine analysts have rated the stock with a hold recommend

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample preparation system design

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.

A Look at Qiagen NV (QGEN) After 3.4% Gain -- GF Value $49.88 vs Price $44.78
On September 21, 2026, Qiagen NV (QGEN) shares rose 3.4% to $44.78, demonstrating a notable increase amidst a challenging year, with a 52-week range of $32.53 t

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Share